# RSV Vaccine Response in Stem Cell and CAR-T Therapy Recipients

> **NCT07296120** · PHASE4 · NOT_YET_RECRUITING · sponsor: **The Cooper Health System** · enrollment: 30 (estimated)

## Conditions studied

- CAR-T Cell Therapy
- RSV Immunization
- Bone Marrow Transplant - Autologous or Allogeneic

## Interventions

- **BIOLOGICAL:** Respiratory Syncytial Virus Prefusion F Vaccine (RSVpreF)

## Key facts

- **NCT ID:** NCT07296120
- **Lead sponsor:** The Cooper Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2027-01-01
- **Final completion:** 2027-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07296120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07296120, "RSV Vaccine Response in Stem Cell and CAR-T Therapy Recipients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07296120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*